Clinical evaluation of the efficacy and safety of Hochuekkito for fatigue in patients with myeloproliferative neoplasms

Clinical evaluation of the efficacy and safety of Hochuekkito for fatigue in patients with myeloproliferative neoplasms - Hochuekkito for myeloproliferative neoplasms related fatigue

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031519

Enrollment

110

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myeloproliferative neoplasms

Interventions

Hochuekkitou 7.5g/day for 8 weeks No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnosed as myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, primary myelofibrosis, and secondary myelofibrosis 2.Score >=3 in fatigue (weariness, tiredness) by circling the one number that best describes your WORST level of fatigue during past 24 hours of MPN-SAF TSS 3.20 years of age or older 4.Written informed consent 5.Capable of oral administration 6.No plan to change the treatment strategy because of stable disease

Exclusion criteria

Exclusion criteria: 1.Severe complications including liver disease and respiratory disease 2.Alergy to chinese traditional medicine 3.Treated with other chinese traditional medicine within 2 weeks. 4.Participated to other clinical trials 5.Determined as inappropriate by the researcher

Design outcomes

Primary

Measure	Time frame
MPN-SAF TSS at week 8	—

Countries

Japan

Contacts

Public ContactYoko Edahiro

Juntendo University School of Medicine Department of Hematology

yedahiro@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026